Study shows injection similarities for Lucentis, Eylea

December 11, 2013

According to a new study that examined the real-world usage of ranibizumab (Lucentis, Genentech) and aflibercept (Eylea, Regeneron), patients with wet age-related macular degeneration (AMD) required an equivalent number of injections over 6- and 12-month periods for both treatments.

 

According to a new study that examined the real-world usage of ranibizumab (Lucentis, Genentech) and aflibercept (Eylea, Regeneron), patients with wet age-related macular degeneration (AMD) required an equivalent number of injections over 6- and 12-month periods for both treatments.

The retrospective analysis will be included in the December issue of Advances in Therapy.

The analysis based on U.S. administrative claim data, compared the number of injections and cost of first-line intravitreal injections between patients who were treated with aflibercept to those treated with ranibizumab for wet AMD.

Key results from 6-month analyses-which included 319 aflibercept patients and 1,054 ranibizumab patients-found that the treatments were used at a similar frequency and also resulted in similar injection costs among wet AMD patients.

In the 12-month analyses-which included 57 aflibercept patients and 374 ranibizumab patients-differences in the frequency of injections and injection costs were also insignificant.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.